Oculis Holding NasdaqGM:OCS 주식 보고서 Oculis Holding AG
NasdaqGM:OCS 주식 보고서
OCS 주식 개요 임상 단계의 바이오 제약 회사인 오큘리스 홀딩 AG는 안과 질환 치료를 위한 신약 후보 물질을 개발하는 회사입니다.
보상 위험 분석 + 1 더 많은 위험
모든 위험 점검 보기 가격 내역 및 성능
다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Oculis Holding 과거 주가 현재 주가 US$15.99 52주 최고치 US$18.00 52주 최저치 US$9.60 베타 0.0083 11개월 변경 7.39% 3개월 변경 사항 39.65% 1년 변경 사항 63.16% 33년 변화 63.50% 5년 변화 n/a IPO 이후 변화 64.85%
최근 뉴스 및 업데이트
Oculis: Lack Of Coverage Only Real Risk For This Solid Company Nov 04
Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer Oct 02
Oculis Holding AG Appoints Sharon Klier as Chief Development Officer Aug 15 Oculis Holding AG to Report Q2, 2024 Results on Aug 14, 2024
Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy Jun 13
Oculis Holding AG Announces Board and Committee Appointments May 30 더 많은 업데이트 보기
Oculis: Lack Of Coverage Only Real Risk For This Solid Company Nov 04
Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer Oct 02
Oculis Holding AG Appoints Sharon Klier as Chief Development Officer Aug 15 Oculis Holding AG to Report Q2, 2024 Results on Aug 14, 2024
Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy Jun 13
Oculis Holding AG Announces Board and Committee Appointments May 30
First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023) May 09 Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million. May 09
Oculis Holding AG, Annual General Meeting, May 29, 2024 May 01
Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million. Apr 24
Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million. Apr 12
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development Apr 10
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Apr 09
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 20
New major risk - Revenue and earnings growth Mar 20
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Dec 21
Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema Dec 19
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease Dec 08
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 17 Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors Nov 17
Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress Oct 11
Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema Oct 06
New major risk - Revenue and earnings growth Oct 01
Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer Sep 12
Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022) Sep 02
Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops Aug 09
Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases Jun 28
High number of new and inexperienced directors Mar 30 주주 수익률 OCS US Pharmaceuticals US 마켓 7D -9.1% 1.1% 5.7% 1Y 63.2% 16.6% 36.9%
전체 주주 수익률 보기
수익률 대 산업: OCS 지난 1년 동안 16.6 %를 반환한 US Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: OCS 지난 1년 동안 36.9 %를 반환한 US 시장을 초과했습니다.
가격 변동성 Is OCS's price volatile compared to industry and market? OCS volatility OCS Average Weekly Movement 7.0% Pharmaceuticals Industry Average Movement 9.4% Market Average Movement 6.2% 10% most volatile stocks in US Market 15.3% 10% least volatile stocks in US Market 3.0%
안정적인 주가: OCS 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: OCS 의 주간 변동성 ( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 임상 단계의 바이오 제약 회사인 오큘리스 홀딩 AG는 안과 질환 치료를 위한 신약 후보물질을 개발합니다. 이 회사의 주요 제품 후보로는 당뇨병성 황반부종 치료를 위한 임상 3상 시험 중인 국소 덱사메타손 옵티리치 제형인 OCS-01, 안구건조증 치료를 위한 임상 2b상 시험 중인 국소 생물학적 후보인 OCS-02, 녹내장, 건성 연령 관련 황반변성 및 당뇨망막증, 급성 시신경염에 대한 적응증을 가진 신경 손상 질환 수정 신경 보호제인 OCS-05가 있습니다. 이 회사는 스위스 추크에 본사를 두고 있습니다.
자세히 보기 Oculis Holding AG 기본 사항 요약 Oculis Holding 의 수익과 매출은 시가총액과 어떻게 비교하나요? OCS 기본 통계 시가총액 US$679.61m 수익(TTM ) -US$79.05m 수익(TTM ) US$985.60k
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) OCS 손익 계산서(TTM ) 수익 CHF 868.00k 수익 비용 CHF 48.35m 총 이익 -CHF 47.48m 기타 비용 CHF 22.14m 수익 -CHF 69.62m
주당 순이익(EPS) -1.67 총 마진 -5,470.16% 순이익 마진 -8,020.85% 부채/자본 비율 0%
OCS 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
